Intracardiac cholinergic ganglia (ICG) neurons receive excitatory input from vagal pre-ganglionic fibers and are critical for the transmission of parasympathetic drive throughout the heart. During disease, electronic vagal stimulation improves cardiac function and reduces arrhythmias. However, vagal stimulation is not selective for efferent or cholinergic fibers and implanting an electronic device before unanticipated episodes of cardiac infarction is not clinically feasible. We addressed these limitations by testing the hypothesis that chemogenetic ICG activation immediately after an infarction would reduce arrhythmia incidence and improve ventricular function. Floxed DREADDs (AAV2-hSyn-DIOhM3D(Gq)-mcherry) were injected into the pericardial sac of neonatal rats that selectively express Cre recombinase in cholinergic neurons. At 8 weeks, hearts were excised for ex-vivo studies and excitatory hM3Dq DREADDs expressed in ICG cholinergic neurons were activated by clozapine-N-oxide (CNO). Heart rate (HR), LV developed pressure, and overall arrhythmia incidence were measured. In healthy hearts, CNO decreased HR for the duration of the experiment (247 ±10.56 to 189.35± 3.46 beats per minute, p<0.0001, n=5). To study ICG activation after infarction, hearts received CNO or saline after complete ligation of the left anterior descending coronary artery or partial obstruction of the left coronary artery. The ECG was analyzed to assess PR interval and arrhythmia incidence, including non-sustained and sustained VT and fibrillation. ICG activation increased PR interval from 39.13 ± 2.75 to 42.46 ± 3.07 ms (p=0.0097, n=5). ICG activation also reduced arrhythmia incidence after coronary artery ligation from 1.65 to 0.6467 arrhythmias per min (p=0.042, n=5), an outcome that is likely motivated by ICG neuron inhibition of adrenergic activity in addition to vasodilation and increased coronary flow. These studies demonstrate that cardiac cholinergic ICG activation following an MI quickly elevates cardiac parasympathetic drive, protecting against arrhythmias. Future studies will focus on measuring the inhibition of adrenergic activity by chemogenetic activation of cholinergic ICG neurons and local coronary flow increases.
Read full abstract